Pacer Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.7M | Buy |
88,863
+12,721
| +17% | +$5.93M | 0.11% | 205 |
|
|
2025
Q4 | $34.5M | Buy |
76,142
+9,641
| +14% | +$4.16M | 0.09% | 231 |
|
|
2025
Q3 | $26M | Buy |
66,501
+26,543
| +66% | +$11.1M | 0.07% | 272 |
|
|
2025
Q2 | $17.8M | Buy |
39,958
+9,262
| +30% | +$4.27M | 0.04% | 346 |
|
|
2025
Q1 | $14.9M | Sell |
30,696
-8,104
| -21% | -$3.78M | 0.03% | 372 |
|
|
2024
Q4 | $15.6M | Buy |
38,800
+6,359
| +20% | +$2.95M | 0.03% | 377 |
|
|
2024
Q3 | $15.1M | Sell |
32,441
-5,885
| -15% | -$2.83M | 0.03% | 377 |
|
|
2024
Q2 | $18M | Buy |
38,326
+1,085
| +3% | +$471K | 0.04% | 341 |
|
|
2024
Q1 | $15.6M | Sell |
37,241
-4,011
| -10% | -$1.7M | 0.04% | 357 |
|
|
2023
Q4 | $16.8M | Buy |
41,252
+11,940
| +41% | +$4.41M | 0.05% | 321 |
|
|
2023
Q3 | $10.2M | Buy |
29,312
+3,510
| +14% | +$1.23M | 0.04% | 324 |
|
|
2023
Q2 | $9.08M | Sell |
25,802
-11,750
| -31% | -$3.96M | 0.04% | 409 |
|
|
2023
Q1 | $11.8M | Buy |
37,552
+22,887
| +156% | +$6.86M | 0.05% | 349 |
|
|
2022
Q4 | $4.23M | Buy |
14,665
+4,439
| +43% | +$1.35M | 0.02% | 466 |
|
|
2022
Q3 | $2.96M | Buy |
10,226
+61
| +0.6% | +$17.6K | 0.02% | 402 |
|
|
2022
Q2 | $2.86M | Sell |
10,165
-2,901
| -22% | -$776K | 0.02% | 416 |
|
|
2022
Q1 | $3.41M | Sell |
13,066
-8,387
| -39% | -$1.99M | 0.03% | 492 |
|
|
2021
Q4 | $4.71M | Sell |
21,453
-7,435
| -26% | -$1.45M | 0.05% | 481 |
|
|
2021
Q3 | $5.24M | Buy |
28,888
+1,945
| +7% | +$380K | 0.07% | 362 |
|
|
2021
Q2 | $5.43M | Buy |
26,943
+2,820
| +12% | +$590K | 0.08% | 323 |
|
|
2021
Q1 | $5.18M | Sell |
24,123
-2,118
| -8% | -$465K | 0.09% | 233 |
|
|
2020
Q4 | $6.2M | Sell |
26,241
-12,246
| -32% | -$2.81M | 0.12% | 135 |
|
|
2020
Q3 | $10.5M | Sell |
38,487
-5,313
| -12% | -$1.47M | 0.22% | 80 |
|
|
2020
Q2 | $12.7M | Buy |
43,800
+22,933
| +110% | +$6.22M | 0.26% | 69 |
|
|
2020
Q1 | $5.64M | Buy |
20,867
+611
| +3% | +$140K | 0.11% | 69 |
|
|
2019
Q4 | $4.43M | Sell |
20,256
-26,602
| -57% | -$5.38M | 0.2% | 82 |
|
|
2019
Q3 | $7.94M | Buy |
46,858
+5,650
| +14% | +$1,000K | 0.18% | 96 |
|
|
2019
Q2 | $7.56M | Buy |
41,208
+4,058
| +11% | +$709K | 0.18% | 91 |
|
|
2019
Q1 | $6.83M | Buy |
+37,150
| New | +$6.86M | 0.19% | 91 |
|
|
2018
Q4 | – | Sell |
-25,079
| Closed | -$4.83M | – | 1034 |
|
|
2018
Q3 | $4.83M | Buy |
25,079
+5,052
| +25% | +$900K | 0.18% | 92 |
|
|
2018
Q2 | $3.4M | Buy |
20,027
+3,606
| +22% | +$559K | 0.15% | 122 |
|
|
2018
Q1 | $2.68M | Buy |
16,421
+2,179
| +15% | +$356K | 0.15% | 129 |
|
|
2017
Q4 | $2.13M | Buy |
14,242
+5,904
| +71% | +$874K | 0.15% | 136 |
|
|
2017
Q3 | $1.27M | Buy |
8,338
+1,129
| +16% | +$170K | 0.11% | 199 |
|
|
2017
Q2 | $929K | Buy |
7,209
+577
| +9% | +$69.5K | 0.09% | 272 |
|
|
2017
Q1 | $725K | Buy |
6,632
+310
| +5% | +$27.3K | 0.09% | 310 |
|
|
2016
Q4 | $466K | Sell |
6,322
-555
| -8% | -$45.2K | 0.07% | 437 |
|
|
2016
Q3 | $600K | Sell |
6,877
-280
| -4% | -$26.5K | 0.09% | 279 |
|
|
2016
Q2 | $616K | Sell |
7,157
-15
| -0.2% | -$1.3K | 0.1% | 239 |
|
|
2016
Q1 | $570K | Buy |
7,172
+248
| +4% | +$22.4K | 0.13% | 165 |
|
|
2015
Q4 | $871K | Buy |
+6,924
| New | +$836K | 0.2% | 103 |
|
Other funds holding VRTX
VCM
VPM
Pacer Advisors's VRTX Position: Q1 2026 in Review
Pacer Advisors increased its Vertex Pharmaceuticals (VRTX) stake by 17% in Q1 2026, buying an estimated $5.93M and bringing the position to 88,863 shares worth $39.7M. The position accounts for 0.11% of the portfolio, ranked #205.
Pacer Advisors first reported a position in VRTX in Q4 2015 and has held it in 41 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- Pacer Advisors held 88,863 shares of Vertex Pharmaceuticals worth $39.7M as of Q1 2026.
- Pacer Advisors bought 12,721 Vertex Pharmaceuticals shares in Q1 2026, an estimated $5.93M.
- Vertex Pharmaceuticals made up 0.11% of Pacer Advisors's portfolio in Q1 2026, its #205 holding.
- Pacer Advisors first reported a position in Vertex Pharmaceuticals in Q4 2015 and has held it in 41 quarters since.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on Pacer Advisors's 13F filing for Q1 2026, filed 6 May 2026.